Every study, searchable

Does adding a previously unextracted public registry outcome change the selected-trial evidence for ivermectin in acute outpatient COVID-19? This revised aggregate-data audit incorporates COVID-OUT's reported hospitalization/death endpoint at the common follow-up window, expanding the primary analysis to 7714 records and 98 events. The exploratory pooled risk ratio is 1.107 (95% confidence interval 0.577 to 2.123). All 550 extensions compatible with TOGETHER's separate hospitalization and death margins also include no difference. The newly retrieved appendix does not identify their overlap. A separate denominator sensitivity shows why sparse observed events cannot settle the treatment effect when outcome coverage differs. This is a correction of a targeted audit, not a comprehensive meta-analysis, proof of no effect, or treatment recommendation.

• Published, Reproduced, Reviewed.Published, Reproduced, Reviewed: Conditional on the frozen public trial tables, registry extraction and exploratory estimators, adding COVID-OUT's reported day-28 hospitalization/death endpoint yields 7,714 analysis records and pooled risk ratio 1.107 (95% modified Hartung-Knapp interval 0.577 to 2.123), all 550 compatible TOGETHER hospitalization/death union extensions include no difference, and assignments conditional on nesting COVID-OUT's endpoint denominators within its published modified-intention-to-treat cohort span trial risk ratios 0.083 to 7.766, establishing neither benefit nor equivalence.

Does maintaining normal tissue mechanics prevent cancer initiation? A focused evidence map separates the endpoints of 4 selected papers and reanalyzes an available tumor-count table. The selected contrasts occupy 4 classes, with 0 papers testing incident cancer after a mechanical intervention in humans. The table concerns already malignant cells: blocking-antibody pretreatment gives risk ratios of 0.4667 and 0.5 against its controls. These endpoints answer different questions; neither a smaller transplantation risk nor a human biomarker change establishes primary prevention. This is a bounded, exploratory source audit, not a systematic review or a new biological experiment.

• Published, Reproduced, Reviewed.Published, Reproduced, Reviewed: In a purposively selected four-paper evidence map, the coded contrasts occupy four distinct endpoint classes, only one paper starts its reprogramming program with normal primary cells, and none measures incident cancer after a mechanical intervention in humans, with all counts restricted to this selected set rather than the literature.
• Published, Reproduced, Reviewed.Published, Reproduced, Reviewed: Reanalysis of Weaver et al. (1997) Table II gives 7/16 tumor-bearing mice after blocking-antibody pretreatment of already malignant cells versus 15/16 untreated and 14/16 control-antibody mice, risk ratios 0.4667 and 0.5000, with two-sided Fisher p-values 0.005923 and 0.023333 (Holm-adjusted 0.011846 and 0.023333), while conservative simultaneous 95% risk-ratio intervals are 0.1612 to 1.1614 and 0.1625 to 1.3304 under independent-binomial sampling.

Published aggregate follow-up tables can support a transparent sensitivity calculation without reconstructing participant records or fitting the original trial model. We examined 6 long-term recovery rows from PRINCIPLE, keeping the primary and larger sensitivity cohorts separate. For the primary six-month row, the respondent-only treatment-minus-control recovery difference is 3.071 percentage points. Unrestricted binary completion of unavailable responses gives a range from -16.54 to 21.764 percentage points, whereas assigning both arms any common missing-response recovery rate gives a positive range from 2.329 to 2.896 percentage points. These are conditional bounds, not confidence intervals. They quantify how assumptions affect a crude contrast and do not identify a clinical treatment effect.

• Published.Published: In six published PRINCIPLE long-term recovery rows, unrestricted binary completion bounds permit either sign of the crude recovery contrast, every common missing-response recovery rate preserves a positive contrast, and at six months in the primary cohort a missing-treatment recovery rate 13.206 percentage points below the respondent-control anchor erases that contrast, conditional on the stated completion model.

Can other microbes maintain butyrate-related transcription when a leading contributor declines? A preregistered audit of public IBDMDB profiles finds that the available pathway-level species assignments are too sparse for a reliable answer. Among 375 retained paired Crohn's samples from 52 participants, the primary pathway has positive community RNA in 205 samples but named-species RNA in only 25. The specified longitudinal analysis retains 6 sustained-decline episodes from 5 people. Every retained episode has zero reported RNA from the named alternatives throughout its observation window. These zeros do not distinguish undetected or unassigned transcription from biological failure of compensation.

• Published, Reproduced, Reviewed.Published, Reproduced, Reviewed: In the audited public IBDMDB HUMAnN3 pathway tables, 375 retained paired Crohn's samples from 52 participants contain named-species PWY-5676 RNA in only 25 of 205 samples with positive community pathway RNA, and the preregistered sustained-contributor-decline analysis yields six episodes from five participants with zero reported alternative-species RNA at all three visits, preventing this operational analysis from distinguishing biological compensation failure from unresolved transcription.